The test MRSA and MSSA directly from blood culture samples in about one hour, compared to between 48 and 72 hours with other methods, the company said.
Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
Performed on the company's Safetube platform, GFC's Microscreen test uses DNA hybridization to detect biomarkers in methicillin-resistant Staphylococcus aureus.
In Science this week: new version of CRISPR that targets RNA, and more.
Using MRSA isolates from England, researchers uncovered hospital-specific, community-specific, and overlapping transmission clusters.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
Scientists studied blood samples from 300 patients with septicemia, examining how different MRSA strains behave and assessing their lethality.
Scientists from The Wellcome Trust Sanger Institute, Public Health England, and elsewhere sequenced the genomes of 209 MRSA isolates collected in Europe from 1960 to 1989.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The test, which simultaneously detects MRSA and Staphylococcus aureus, is designed to run on the company's Liat PCR point-of-care platform.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.